Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis

Amyloid

Volumn 21, Issue 1, 2014, Pages 35-44

  Glaudemans, Andor W J M ^a   Van Rheenen, Ronald W J ^a   Van Den Berg, Maarten P ^a   Noordzij, Walter ^a   Koole, Michel ^a   Blokzijl, Hans ^a   Dierckx, Rudi A J O ^a   Slart, Riemer H J A ^a   Hazenberg, Bouke P C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amyloidosis; ATTR; Bone scintigraphy; Cardiac amyloidosis; Cardiac biomarkers; Echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; OXIDRONATE TECHNETIUM TC 99M; PREALBUMIN; TROPONIN T;

AMYLOIDOSIS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD VESSEL WALL; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; GAMMA CAMERA; GENE MUTATION; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART TO SKULL RATIO; HEART TO WHOLE BODY RATIO; HETEROZYGOTE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MALE; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSTHYRETIN SYSTEMIC AMYLOIDOSIS;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; BONE AND BONES; CARDIOMYOPATHIES; EARLY DIAGNOSIS; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TISSUE DISTRIBUTION;

EID: 84896726189     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.871250     Document Type: Article

References (31)

1. Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.
2. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.
3. Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am 2013;39:323-45.
4. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120: 1203-12.
5. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7: 398-408.
6. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-15.
7. Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009;16:9-14.
8. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30.
9. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10.
10. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, et al. Usefulness and limitations of 99mTc-3,3- diphosphono-1,2- propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.
11. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Rocken C, Hardt S, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164:179-84.
12. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretinrelated cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4: 659-70.
13. Hazenberg BP, van Schijndel B, Bijzet J, Limburg PC, Bos R, Haagsma EB. Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis. Amyloid 2011;18:79.
14. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
16. Hummel YM, Klip IJ, de Jong RM, Pieper PG, van Veldhuisen DJ, Voors AA. Diastolic function measurements and diagnostic consequences: a comparison of pulsed wave- and color-coded tissue Doppler imaging. Clin Res Cardiol 2010;99:453-8.
17. Piper C, Butz T, Farr M, Faber L, Oldenburg O, Horstkotte D. How to diagnose cardiac amyloidosis early: impact of ECG, tissue Doppler echocardiography, and myocardial biopsy. Amyloid 2010; 17:1-9.
18. Knapp CM, Sarodia U, Brown L, Bibby K. Primary nonfamilial ocular amyloidosis. Eye (Lond) 2003;17:252-4.
19. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
20. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 2008;51:1509-10.
21. Soon E, Doughty NJ, Treacy CM, Ross RM, Toshner M, Upton PD, Sheares K, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. Pulm Circ 2011;1:244-9.
22. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77:64-71.
23. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, Ferlini A, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53.
24. Fruhling J, Verbist A, Balikdjian D. Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)? Nucl Med Commun 1986;7:415-25.
25. Pauwels EK, Blom J, Camps JA, Hermans J, Rijke AM. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med 1983;8:118-22.
26. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Larif F, Maurer MS. (99m)Tc-pyrophospate scintigraphy for differentiating lightchain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6: 195-201.
27. Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, Slart RH. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609-17.
28. Noordzij W, Glaudemans AW, Slart RH, Dierckx RA, HazenbergBP. Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis. Amyloid 2012;19: 208-11.
29. Janssen S, van Rijswijk MH, Piers DA, de Jong GM. Soft-tissue uptake of 99mTc-diphosphonate in systemic AL amyloidosis. Eur J Nucl Med 1984;9:538-41.
30. Yood RA, Skinner M, Cohen AS, LeeVW. Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatol 1981;8:760-6.
31. Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet 1977;1:92-3.